Pharma heavyweight named CEO at PBM

14 March 2018

A year after relinquishing the leadership of the UK’s leading drugmaker, Sir Andrew Witty (pictured above) has been named chief executive of a fast-growing player in the pharmacy benefit manager (PBM) space.

Sir Andrew led GlaxoSmithKline (LSE: GSK) from 2008 to 2017, gaining plenty of experience of the payer dynamics of the US pharma market, and that understanding will be vital in his new role as CEO of Optum, which is part of the UnitedHealth Group (NYSE: UNH) and includes OptumRx, one of the USA’s largest PBMs.

"He has deep experience with how data and analytics and new technologies can be used to improve patient outcomes, better serve consumers, lower costs and drive value across the system"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK